To further explore whether AGO2 is involved in the mRNA degradation of ouabain-treated DLBCL cells, we performed mRNA half-life on LSM1 and DCP1A, which were enriched in the RNA degradation pathway after treatment with ouabain. Here, AGO2 is linked to diffuse large B-cell lymphoma.